Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31124766 | 0.81 | TSHR (0.35) | TACR1SMN1; SMN2TSHR | |
| SCHEMBL8149467 | 0.80 | GABRA1 (0.41) | SMN1; SMN2KDM4E | |
| SCHEMBL31124717 | 0.79 | TRPA1 (0.35) | TACR1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL9347235 | 0.78 | ESR1 (0.43) | ALDH1A1 | |
| SCHEMBL17803752 | 0.78 | ACLY (0.34) | SMN1; SMN2KDM4E | |
| SCHEMBL1314001 | 0.77 | AGXT (0.42) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL8024443 | 0.76 | MRGPRX4 (0.38) | RAB9ASMN1; SMN2TSHR | |
| SCHEMBL5113620 | 0.76 | MRGPRX4 (0.48) | ALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL16818604 | 0.76 | TACR1 (0.34) | TACR1SMN1; SMN2TSHR | |
| SCHEMBL22774158 | 0.76 | SMYD2 (0.32) | TACR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | TACR1 343/4885ALDH1A1 1527/4885RAB9A 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.